Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-On the radar: Corporate top news overload

Wed, 30th Oct 2019 07:37

* European shares seen opening little changed

* Fiat Chrysler and PSA confirm tie-up talks

* Bank earnings in focus: DB, CS, StanChart, Santander

* Federal Reserve seen cutting rates, focus on policy outlook
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters and anchored today by Julien Ponthus. Reach him on Messenger to share your
thoughts on market moves: julien.ponthus.thomsonreuters.com@reuters.net

ON THE RADAR: CORPORATE TOP NEWS OVERLOAD (0736 GMT)

Futures have opened sideways with no clear directional trend in Europe.

What's clear however is that there is such a huge flow of corporate news that it will be
difficult to be sure not to have missed anything before the open and the market, which tends to
be quite unforgiving these days, gives its verdict.

Before getting in the Q3 action, let's first flag out a major piece of news in the auto
industry with Fiat Chrysler confirming talks with French rival PSA for a
potential tie-up.

News of the tentative merger comes as Germany's Volkswagen lowered its full-year
outlook for vehicle deliveries, warning of slowing demand.

Lots to take in the banking industry too:

Deutsche Bank reports 832 million euro Q3 loss on restructuring

StanChart flags growth, interest rate headwinds after Q3 profit beat

Credit Suisse doubles Q3 net profit

Santander Q3 net profit falls 75% as UK charges offset Brazil strength

But there are heavyweights across all sectors making headlines this morning so in no
particular order, he's the rest of the top news: click here to get it on Eikon:

Airbus cuts delivery goal on Hamburg plant snags

Record Q3 output boosts Total's cash flow, low prices hit profit

Lower oil and gas prices weigh on OMV Q3 profit

Bayer says number of glyphosate plaintiffs jumps to 42,700

Clariant Q3 profit and sales fall as economic climate worsens

Angry Birds maker Rovio's Q3 profit halves year-on-year

EssilorLuxottica confirms 2019 targets after stronger Q3 sales

Britain's Next keeps full year guidance after Q3 sales rise

(Julien Ponthus)

*****

FED WATCHING, Q3 GALORE AND THE XMAS BREXIT ELECTION (0542 GMT)

Christmas will come early to the UK this year, precisely on December 12 in the form of a UK
general election.

It's far from certain however that the polls will deliver anything on Boris Johnson or
Jeremy Corbyn's wish list but less than 48 hours ahead of Halloween, investors aren't spooked by
the prospect of the process going all wrong.

The pound is roughly stable at 1.2870 and according to IG, financial spreadbetters expect
London's FTSE to open just 7 points lower, so nothing dramatic there indeed.

Frankfurt's DAX is also seen retreating slightly at the open by 25 points but Paris is
should be flat.

With Wall Street on and off record highs, the Fed's meeting today and the expected interest
rate cut will be key, especially after it emerged that Washington and Beijing may not complete
their interim trade agreement in time to sign in Chile next month.

Amid all that news let us not forget that we are in for one of the busiest day of the Q3
season with a flurry of results such as Bayer, GlaxoSmithKline, Suez
or Total.

Last but not least, there will also be a deluge of indicators from the euro zone which
should shed more light on whether there is light to be seen at the end of the macro gloom
tunnel.

(Julien Ponthus)

*****
(Reporting by Danilo Masoni, Joice Alves, Julien Ponthus and Thyagaraju Adinarayan)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.